3 Small-Cap Biotechs With Binary Catalysts on the Calendar Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.
Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Kodiak Sciences Stock Is Surging Friday: What's Driving The Action? Kodiak Sciences Inc (
NASDAQ: KOD ) shares are trading higher Friday after positive Phase 3 GLOW2 results for Zenkuda in diabetic retinopathy.
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study. The trial, which evaluated the company's lead product candidate Zenkuda™ (tarcocimab tedromer) in patients with diabetic retinopathy (DR), not
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions.
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.
These stocks are gapping in today's session There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Wednesday.
Gapping stocks in Monday's session Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
